TR199900100T2 - Yüksek-çekimi interlökin-4 muteinleri. - Google Patents

Yüksek-çekimi interlökin-4 muteinleri.

Info

Publication number
TR199900100T2
TR199900100T2 TR1999/00100T TR9900100T TR199900100T2 TR 199900100 T2 TR199900100 T2 TR 199900100T2 TR 1999/00100 T TR1999/00100 T TR 1999/00100T TR 9900100 T TR9900100 T TR 9900100T TR 199900100 T2 TR199900100 T2 TR 199900100T2
Authority
TR
Turkey
Prior art keywords
muteins
mutein
helix
amino acid
positions
Prior art date
Application number
TR1999/00100T
Other languages
English (en)
Inventor
Greve Jeffrey
B. Shanafelt Armen
Roczniak Steven
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of TR199900100T2 publication Critical patent/TR199900100T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vahsi tipli IL-4'e göre numaralandirilmis bir rekombinant insan IL-4 muteini olup, bu mutein, vahsi tipli IL-4'ün ya A- ya da C-alfa helislerinin baglanma yüzeyinde en azindan bir amino asidi ikamesini içermekte, bu sayede, mutein nativ IL-4'e göre en azindan daha büyük çekim (afinite) ile IL-4Ralfa reseptörüne baglanmaktadir. Ikame, daha tercihan, A-helisinde, 13 ve 16 konumlarini ve C-helisinde, 81 ve 89 konumlarini kapsayan gruptan seçilmektedir. En tercih edilen düzenleme, 13 konumundaki ikamenin Thr-Asp oldugu rekombinant insan IL-4 muteinidir. Muteinleri kodlayan polinükleotid dizileri, amino asit ve farmasötik bilesimler, dönüstürülmüs konukçu hücreler, muteinlere karsi antikorlar da anlatilmistir.
TR1999/00100T 1996-07-19 1997-07-09 Yüksek-çekimi interlökin-4 muteinleri. TR199900100T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68780396A 1996-07-19 1996-07-19

Publications (1)

Publication Number Publication Date
TR199900100T2 true TR199900100T2 (tr) 1999-04-21

Family

ID=24761912

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00100T TR199900100T2 (tr) 1996-07-19 1997-07-09 Yüksek-çekimi interlökin-4 muteinleri.

Country Status (23)

Country Link
EP (1) EP0939817B1 (tr)
JP (1) JP2000515016A (tr)
KR (1) KR100468553B1 (tr)
CN (1) CN1201006C (tr)
AR (2) AR007917A1 (tr)
AT (1) ATE310821T1 (tr)
AU (1) AU718794B2 (tr)
BR (1) BR9710733B1 (tr)
CA (1) CA2259940C (tr)
DE (1) DE69734723T2 (tr)
DK (1) DK0939817T3 (tr)
ES (1) ES2252786T3 (tr)
HU (1) HU224973B1 (tr)
ID (1) ID17491A (tr)
IL (2) IL127934A0 (tr)
MY (1) MY124565A (tr)
NZ (2) NZ333748A (tr)
PL (1) PL188738B1 (tr)
RU (1) RU2202364C2 (tr)
TR (1) TR199900100T2 (tr)
TW (1) TW496871B (tr)
WO (1) WO1998003654A2 (tr)
ZA (1) ZA976368B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
EP1022337B1 (en) * 1999-01-20 2006-07-26 Bayer HealthCare AG Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
EP1022339B1 (en) 1999-01-20 2006-02-01 Bayer HealthCare AG Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
CN1306030C (zh) * 2001-09-28 2007-03-21 中山大学 一种人白细胞介素－10基因序列及含该基因序列的大肠杆菌
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
RU2389796C2 (ru) * 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
MX2007012887A (es) * 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
WO2017001568A1 (en) 2015-07-01 2017-01-05 Universitat De Lleida Treatment and prevention of amyotrophic lateral sclerosis
CN113227369B (zh) * 2018-12-19 2025-09-12 生物制药翻译学院德绍研究有限公司 具有改善的酶学特性的胰蛋白酶变体
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN112442504B (zh) * 2020-12-10 2023-01-24 电子科技大学 一种重组草鱼白介素-12活性蛋白的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
AU4289193A (en) * 1992-04-17 1993-11-18 University Hospital, The Mutant cytokines having increased receptor affinity
RU2235728C2 (ru) * 1996-06-14 2004-09-10 Байер Корпорэйшн Мутеин человеческого il-4, полинуклеотидная молекула, вектор, линия sf9, трансформированная вектором, способ выбора мутеина, фармацевтическая композиция для активирования т-клеток, способ лечения пациента, страдающего заболеванием, поддающимся лечению il-4

Also Published As

Publication number Publication date
PL188738B1 (pl) 2005-04-29
ID17491A (id) 1998-01-08
HUP0000248A3 (en) 2003-09-29
HU224973B1 (en) 2006-04-28
AU718794B2 (en) 2000-04-20
EP0939817A2 (en) 1999-09-08
MY124565A (en) 2006-06-30
AU3654597A (en) 1998-02-10
KR20000067914A (ko) 2000-11-25
NZ333748A (en) 2000-08-25
WO1998003654A3 (en) 1998-05-14
NZ505238A (en) 2001-06-29
HUP0000248A2 (hu) 2000-06-28
BR9710733A (pt) 1999-08-17
ZA976368B (en) 1998-02-19
HK1022717A1 (en) 2000-08-18
ES2252786T3 (es) 2006-05-16
CA2259940A1 (en) 1998-01-29
BR9710733B1 (pt) 2012-02-22
CA2259940C (en) 2008-09-23
DE69734723T2 (de) 2006-06-22
IL182509A0 (en) 2007-09-20
WO1998003654A2 (en) 1998-01-29
DE69734723D1 (de) 2005-12-29
RU2202364C2 (ru) 2003-04-20
ATE310821T1 (de) 2005-12-15
CN1201006C (zh) 2005-05-11
TW496871B (en) 2002-08-01
KR100468553B1 (ko) 2005-01-29
PL331253A1 (en) 1999-07-05
IL127934A0 (en) 1999-11-30
DK0939817T3 (da) 2006-01-23
IL182509A (en) 2011-03-31
AR007917A1 (es) 1999-11-24
EP0939817B1 (en) 2005-11-23
AR060630A2 (es) 2008-07-02
CN1230223A (zh) 1999-09-29
JP2000515016A (ja) 2000-11-14

Similar Documents

Publication Publication Date Title
Arenberg et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer
Driggers et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
Chouaib et al. More insights into the complex physiology of TNF
TR200003281T2 (tr) CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
NO941142L (no) Tumor-nekrosefaktormuteiner
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
DE69131580D1 (de) GDF-1 und UOG1 Proteine
RU2003110571A (ru) Модуляция il-2- и il-15-опосредованных т-клеточных ответов
DE69434985D1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
MY124565A (en) High-affinity interleukin-4-muteins
DK1273304T3 (da) Anvendelse af interleukin 15
SE9002589L (sv) Neutrofil-aktiverande peptid-2
RU2009104749A (ru) Рекомбинантные белки, подобные человеческому интреферону
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
ATE255638T1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
Taniguchi Regulation of interferon-β gene: structure and function of cis-elements and trans-acting factors
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
Öberg et al. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors
Brand et al. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes
Seelig et al. Synthetic mimics of juxtaposed amino-and carboxyl-terminal peptide domains of human gamma interferon block ligand binding to human gamma interferon receptor.
TR199700842T1 (tr) Insan DNase I Varyantlari.
TR199802591T2 (tr) T-Hücresi seçici interlökin-4 agonistleri